Cited by 109Colorectal Cancer Screening and DetectionInflammatory Bowel DiseaseGenetic factors in colorectal cancer

High risk of advanced colorectal neoplasia in patients with primary sclerosing cholangitis associated with inflammatory bowel disease

Open access
Shah, Shailja C., ten Hove, Joren R., Castaneda, Daniel, Palmela, Carolina, Mooiweer, Erik, Colombel, Jean-Frédéric, Harpaz, Noam, Ullman, Thomas A. +9 more·2018·Clinical Gastroenterology and Hepatology

Abstract

Background & aims Patients with inflammatory bowel disease (IBD) and primary sclerosing cholangitis (PSC, termed PSC-IBD) are at increased risk for colorectal cancer, but their risk following a diagnosis of low-grade dysplasia (LGD) is not well described. We aimed to determine the rate of advanced colorectal neoplasia (aCRN), defined as high-grade dysplasia and/or colorectal cancer, following a diagnosis of indefinite dysplasia or LGD in this population.Methods We performed a retrospective, longitudinal study of 1911 patients with colonic IBD (293 with PSC and 1618 without PSC) who underwent more than 2 surveillance colonoscopies from 2000 through 2015 in The Netherlands or the United States (9265 patient-years of follow-up evaluation). We collected data on clinical and demographic features of patients, as well as data from each surveillance colonoscopy and histologic report. For each surveillance colonoscopy, the severity of active inflammation was documented. The primary outcome was a diagnosis of aCRN during follow-up evaluation. We also investigated factors associated with aCRN in patients with or without a prior diagnosis of indefinite dysplasia or LGD.Results Patients with PSC-IBD had a 2-fold higher risk of developing aCRN than patients with non-PSC IBD. Mean inflammation scores did not differ significantly between patients with PSC-IBD (0.55) vs patients with non-PSC IBD (0.56) (P = .89), nor did proportions of patients with LGD (21% of patients with PSC-IBD vs 18% of patients with non-PSC IBD) differ significantly (P = .37). However, the rate of aCRN following a diagnosis of LGD was significantly higher in patients with PSC-IBD (8.4 per 100 patient-years) than patients with non-PSC IBD (3.0 per 100 patient-years; P = .01). PSC (adjusted hazard ratio [aHR], 2.01; 95% CI, 1.09-3.71), increasing age (aHR 1.03; 95% CI, 1.01-1.05), and active inflammation (aHR, 2.39; 95% CI, 1.63-3.49) were independent risk factors for aCRN. Dysplasia was more often endoscopically invisible in patients with PSC-IBD than in patients with non-PSC IBD.Conclusions In a longitudinal study of almost 2000 patients with colonic IBD, PSC remained a strong independent risk factor for aCRN. Once LGD is detected, aCRN develops at a higher rate in patients with PSC and is more often endoscopically invisible than in patients with only IBD. Our findings support recommendations for careful annual colonoscopic surveillance for patients with IBD and PSC, and consideration of colectomy once LGD is detected.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cgh.2018.01.023

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Chronic inflammation in IBD is associated with increased risk for colorectal malignancy.

    “Also, chronic inflammation in IBD is associated with increased risk for colorectal malignancy.359,[369][370][371]”

    From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [370]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Sinakos E, Samuel S, Enders F, et al. Inflammatory bowel dis- ease in primary sclerosing cholangitis. Inflamm Bowel Dis 2013; 19:1004-1009.

Cited by

Sorted by citations

Authors
Shah, S. C., ten Hove, J. R., Castaneda, D., Palmela, C., Mooiweer, E., Colombel, J.-F., Harpaz, N., Ullman, T. A., van Bodegraven, A. A., Jansen, J. M., Mahmmod, N., van der Meulen-de Jong, A. E., Ponsioen, C. Y., van der Woude, C. J., Oldenburg, B., Itzkowitz, S. H., & Torres, J.
Affiliations
  • Vanderbilt University Medical Center (US)
  • Icahn School of Medicine at Mount Sinai (US)
  • University Medical Center Utrecht (NL)
  • OLVG (NL)
  • St. Antonius Ziekenhuis (NL)
  • Amsterdam UMC Location University of Amsterdam (NL)
  • Hospital Beatriz Ângelo (PT)
Corresponding author
Torres, Joana
Venue
Clinical Gastroenterology and Hepatology
Publisher
Elsevier BV
Published
2018-07
Volume
16
Issue
7
Pages
1106-1113.e3
ISSN
1542-3565 (ISSN-L)
OpenAlex
W2786161279
Cited by
109
References
43
Citations by year
2026: 4 · 2025: 19 · 2024: 10 · 2023: 17 · 2022: 12 · 2021: 11 · 2020: 18 · 2019: 13 · 2018: 5
FWCI
4.41
Type
journal article
Language
en
Open access
Locations
  • Clinical Gastroenterology and Hepatology (publishedVersion)
  • PubMed (publishedVersion)
  • Leiden Repository (Leiden University) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
  • Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
  • Pure Amsterdam UMC (submittedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion)
Funders
National Institute of Diabetes and Digestive and Kidney Diseases (P30DK058404)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Screening and Detection
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Inflammatory Bowel Disease
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords
primary sclerosing cholangitis, inflammatory bowel disease, advanced colorectal neoplasia, colorectal cancer, low-grade dysplasia, high-grade dysplasia, colonic dysplasia, colonic inflammation, surveillance colonoscopy, risk factors, colitis-associated colorectal cancer, Crohn's disease, ulcerative colitis, sex differences, alcohol consumption
MeSH terms
Adolescent, Adult, Colonoscopy, Female, Histocytochemistry, Humans, Longitudinal Studies, Male, Middle Aged, Netherlands, Retrospective Studies, United States, Colorectal Neoplasms, Cholangitis, Sclerosing, Inflammatory Bowel Diseases, Risk Assessment, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review